Trade Humacyte, Inc. - HUMA CFD
Add to favourite- Summary
- Historical Data
- Events
- Income Statement
- Balance Sheet
- Cash Flow
Spread | 0.05 | ||||||||
Long position overnight fee
Long position overnight fee
Go to platform | -0.026179% | ||||||||
Short position overnight fee
Short position overnight fee
Go to platform | 0.003957% | ||||||||
Overnight fee time | 21:00 (UTC) | ||||||||
Min traded quantity | 1 | ||||||||
Currency | USD | ||||||||
Margin | 5% | ||||||||
Stock exchange | United States of America | ||||||||
Commission on trade | 0% |
*Information provided by Capital.com
Prev. Close* | 3.07 |
Open* | 3.08 |
1-Year Change* | -4.64% |
Day's Range* | 3.05 - 3.09 |
52 wk Range | 1.96-5.60 |
Average Volume (10 days) | 282.45K |
Average Volume (3 months) | 9.24M |
Market Cap | 268.26M |
P/E Ratio | -100.00K |
Shares Outstanding | 103.58M |
Revenue | N/A |
EPS | -0.87 |
Dividend (Yield %) | N/A |
Beta | -100.00K |
Next Earnings Date | Mar 22, 2024 |
All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
Date | Close | Change | Change (%) | Open | High | Low |
---|---|---|---|---|---|---|
Mar 27, 2024 | 3.07 | -0.03 | -0.97% | 3.10 | 3.23 | 3.05 |
Mar 26, 2024 | 3.05 | -0.10 | -3.17% | 3.15 | 3.17 | 3.03 |
Mar 25, 2024 | 3.12 | -0.28 | -8.24% | 3.40 | 3.40 | 3.11 |
Mar 22, 2024 | 3.28 | -0.31 | -8.64% | 3.59 | 3.59 | 3.24 |
Mar 21, 2024 | 3.58 | 0.04 | 1.13% | 3.54 | 3.63 | 3.54 |
Mar 20, 2024 | 3.48 | -0.02 | -0.57% | 3.50 | 3.57 | 3.39 |
Mar 19, 2024 | 3.46 | 0.02 | 0.58% | 3.44 | 3.58 | 3.41 |
Mar 18, 2024 | 3.48 | 0.09 | 2.65% | 3.39 | 3.59 | 3.25 |
Mar 15, 2024 | 3.21 | 0.10 | 3.22% | 3.11 | 3.27 | 3.11 |
Mar 14, 2024 | 3.14 | -0.09 | -2.79% | 3.23 | 3.27 | 3.10 |
Mar 13, 2024 | 3.26 | 0.02 | 0.62% | 3.24 | 3.36 | 3.22 |
Mar 12, 2024 | 3.28 | 0.18 | 5.81% | 3.10 | 3.32 | 3.02 |
Mar 11, 2024 | 3.08 | -0.19 | -5.81% | 3.27 | 3.38 | 3.02 |
Mar 8, 2024 | 3.34 | 0.01 | 0.30% | 3.33 | 3.49 | 3.28 |
Mar 7, 2024 | 3.24 | -0.09 | -2.70% | 3.33 | 3.34 | 3.20 |
Mar 6, 2024 | 3.34 | -0.14 | -4.02% | 3.48 | 3.49 | 3.15 |
Mar 5, 2024 | 3.45 | -0.04 | -1.15% | 3.49 | 3.58 | 3.34 |
Mar 4, 2024 | 3.50 | 0.20 | 6.06% | 3.30 | 3.67 | 3.30 |
Mar 1, 2024 | 3.22 | 0.24 | 8.05% | 2.98 | 3.49 | 2.98 |
Feb 29, 2024 | 4.31 | -0.06 | -1.37% | 4.37 | 4.45 | 4.23 |
Humacyte, Inc. Events
Time (UTC) | Country | Event |
---|---|---|
Friday, May 10, 2024 | ||
Time (UTC) 12:30 | Country US
| Event Q1 2024 Humacyte Inc Earnings Release Q1 2024 Humacyte Inc Earnings ReleaseForecast -Previous - |
Thursday, June 6, 2024 | ||
Time (UTC) 12:00 | Country US
| Event Humacyte Inc Annual Shareholders Meeting Humacyte Inc Annual Shareholders MeetingForecast -Previous - |
- Annual
- Quarterly
2022 | 2021 | 2020 | 2019 | |
---|---|---|---|---|
Total revenue | 1.565 | 1.263 | 1.491 | 6.187 |
Revenue | 1.565 | 1.263 | 1.491 | 6.187 |
Total Operating Expense | 86.143 | 79.187 | 66.091 | 91.878 |
Selling/General/Admin. Expenses, Total | 22.883 | 21.13 | 12.013 | 16.275 |
Research & Development | 63.26 | 61.341 | 54.078 | 75.603 |
Unusual Expense (Income) | 0 | -3.284 | 0 | 0 |
Operating Income | -84.578 | -77.924 | -64.6 | -85.691 |
Interest Income (Expense), Net Non-Operating | -3.571 | -4.332 | -1.924 | 0.269 |
Net Income Before Taxes | -11.965 | -26.477 | -66.524 | -85.422 |
Net Income After Taxes | -11.965 | -26.477 | -66.524 | -85.422 |
Net Income Before Extra. Items | -11.965 | -26.477 | -66.524 | -85.422 |
Net Income | -11.965 | -26.477 | -66.524 | -85.422 |
Income Available to Common Excl. Extra. Items | -11.965 | -26.477 | -66.524 | -85.422 |
Income Available to Common Incl. Extra. Items | -11.965 | -26.477 | -66.524 | -85.422 |
Diluted Net Income | -11.965 | -26.477 | -66.524 | -85.422 |
Diluted Weighted Average Shares | 103.051 | 103.003 | 103.003 | 103.003 |
Diluted EPS Excluding Extraordinary Items | -0.11611 | -0.25705 | -0.64584 | -0.82931 |
Dividends per Share - Common Stock Primary Issue | 0 | 0 | 0 | |
Diluted Normalized EPS | -0.11611 | -0.28893 | -0.64584 | -0.82931 |
Other, Net | 76.184 | 55.779 |
Jun 2023 | Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | |
---|---|---|---|---|---|
Total revenue | 0 | 0 | 0 | 0.031 | 1.301 |
Revenue | 0 | 0 | 0 | 0.031 | 1.301 |
Total Operating Expense | 26.045 | 22.512 | 20.79 | 23.525 | 19.832 |
Selling/General/Admin. Expenses, Total | 6.191 | 5.234 | 5.833 | 6.188 | 5.18 |
Research & Development | 20.54 | 17.278 | 14.957 | 17.337 | 14.652 |
Operating Income | -26.045 | -22.512 | -20.79 | -23.494 | -18.531 |
Interest Income (Expense), Net Non-Operating | -0.231 | -0.224 | -0.225 | -0.758 | -1.187 |
Other, Net | 3.57 | -14.233 | 17.295 | -1.029 | 56.586 |
Net Income Before Taxes | -22.706 | -36.969 | -3.72 | -25.281 | 36.868 |
Net Income After Taxes | -22.706 | -36.969 | -3.72 | -25.281 | 36.868 |
Net Income Before Extra. Items | -22.706 | -36.969 | -3.72 | -25.281 | 36.868 |
Net Income | -22.706 | -36.969 | -3.72 | -25.281 | 36.868 |
Income Available to Common Excl. Extra. Items | -22.706 | -36.969 | -3.72 | -25.281 | 36.868 |
Income Available to Common Incl. Extra. Items | -22.706 | -36.969 | -3.72 | -25.281 | 36.868 |
Diluted Net Income | -22.706 | -36.969 | -3.72 | -25.281 | 36.868 |
Diluted Weighted Average Shares | 103.362 | 103.264 | 103.163 | 103.032 | 103.908 |
Diluted EPS Excluding Extraordinary Items | -0.21968 | -0.35801 | -0.03606 | -0.24537 | 0.35481 |
Dividends per Share - Common Stock Primary Issue | 0 | 0 | 0 | 0 | |
Diluted Normalized EPS | -0.22631 | -0.35801 | -0.03606 | -0.24537 | 0.35481 |
Unusual Expense (Income) | -0.686 | 0 | 0 | 0 |
- Annual
- Quarterly
2022 | 2021 | 2020 | 2019 | |
---|---|---|---|---|
Total Current Assets | 154.208 | 229.34 | 41.449 | 94.954 |
Cash and Short Term Investments | 151.879 | 225.502 | 39.929 | 93.713 |
Cash & Equivalents | 149.772 | 217.502 | 39.929 | 93.713 |
Total Receivables, Net | 0.031 | 0.176 | 0.113 | 0.601 |
Accounts Receivable - Trade, Net | 0.031 | 0.176 | 0.113 | 0.601 |
Prepaid Expenses | 2.298 | 3.662 | 1.407 | 0.64 |
Total Assets | 204.302 | 286.533 | 106.688 | 168.691 |
Property/Plant/Equipment, Total - Net | 50.094 | 57.193 | 65.239 | 73.737 |
Property/Plant/Equipment, Total - Gross | 76.275 | 77.633 | 79.5 | 82.154 |
Accumulated Depreciation, Total | -26.181 | -20.44 | -14.261 | -8.417 |
Other Long Term Assets, Total | 0 | 0 | ||
Total Current Liabilities | 19.58 | 11.05 | 11.233 | 10.842 |
Accounts Payable | 1.595 | 2.094 | 2.274 | 3.272 |
Accrued Expenses | 7.158 | 6.802 | 4.634 | 6.07 |
Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 |
Current Port. of LT Debt/Capital Leases | 10.827 | 1.981 | 4.18 | 1.5 |
Other Current Liabilities, Total | 0 | 0.173 | 0.145 | 0 |
Total Liabilities | 87.374 | 164.359 | 36.016 | 36.49 |
Total Long Term Debt | 39.189 | 48.47 | 23.912 | 24.819 |
Long Term Debt | 20.336 | 27.361 | 0.822 | 0 |
Capital Lease Obligations | 18.853 | 21.109 | 23.09 | 24.819 |
Deferred Income Tax | 0 | 0.144 | 0 | |
Other Liabilities, Total | 28.605 | 104.839 | 0.727 | 0.829 |
Total Equity | 116.928 | 122.174 | 70.672 | 132.201 |
Redeemable Preferred Stock | 420.989 | 420.989 | ||
Common Stock | 0.01 | 0.01 | 0.022 | 0.021 |
Additional Paid-In Capital | 543.456 | 536.737 | 37.757 | 32.763 |
Retained Earnings (Accumulated Deficit) | -426.538 | -414.573 | -388.096 | -321.572 |
Total Liabilities & Shareholders’ Equity | 204.302 | 286.533 | 106.688 | 168.691 |
Total Common Shares Outstanding | 103.229 | 103.004 | 103.003 | 103.003 |
Short Term Investments | 2.107 | 8 |
Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | Sep 2022 | |
---|---|---|---|---|---|
Total Current Assets | 102.851 | 120.562 | 133.855 | 154.208 | 174.612 |
Cash and Short Term Investments | 99.986 | 114.604 | 131.677 | 151.879 | 171.731 |
Cash & Equivalents | 99.986 | 114.604 | 129.57 | 149.772 | 163.731 |
Total Receivables, Net | 0 | 0 | 0 | 0.031 | 0.031 |
Accounts Receivable - Trade, Net | 0 | 0 | 0 | 0.031 | 0.031 |
Prepaid Expenses | 2.721 | 5.958 | 2.178 | 2.298 | 2.85 |
Total Assets | 149.385 | 168.106 | 182.976 | 204.302 | 226.219 |
Property/Plant/Equipment, Total - Net | 45.679 | 47.544 | 49.121 | 50.094 | 51.607 |
Property/Plant/Equipment, Total - Gross | 75.927 | 76.477 | 76.86 | 76.275 | 76.599 |
Accumulated Depreciation, Total | -30.248 | -28.933 | -27.739 | -26.181 | -24.992 |
Other Long Term Assets, Total | 0.855 | ||||
Total Current Liabilities | 15.137 | 11.388 | 23.601 | 19.58 | 17.906 |
Accounts Payable | 3.018 | 2.362 | 1.954 | 1.595 | 3.255 |
Accrued Expenses | 9.638 | 6.622 | 6.461 | 7.158 | 8.007 |
Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 |
Current Port. of LT Debt/Capital Leases | 2.481 | 2.404 | 15.186 | 10.827 | 6.471 |
Other Current Liabilities, Total | 0 | 0.173 | |||
Total Liabilities | 112.392 | 106.989 | 101.089 | 87.374 | 107.547 |
Total Long Term Debt | 16.96 | 17.614 | 34.662 | 39.189 | 43.728 |
Long Term Debt | 0 | 0 | 16.41 | 20.336 | 24.286 |
Capital Lease Obligations | 16.96 | 17.614 | 18.252 | 18.853 | 19.442 |
Deferred Income Tax | |||||
Other Liabilities, Total | 80.295 | 77.987 | 42.826 | 28.605 | 45.913 |
Total Equity | 36.993 | 61.117 | 81.887 | 116.928 | 118.672 |
Redeemable Preferred Stock | |||||
Common Stock | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 |
Additional Paid-In Capital | 549.191 | 547.32 | 545.384 | 543.456 | 541.48 |
Retained Earnings (Accumulated Deficit) | -512.208 | -486.213 | -463.507 | -426.538 | -422.818 |
Total Liabilities & Shareholders’ Equity | 149.385 | 168.106 | 182.976 | 204.302 | 226.219 |
Total Common Shares Outstanding | 103.461 | 103.408 | 103.329 | 103.229 | 103.099 |
Short Term Investments | 0 | 0 | 2.107 | 2.107 | 8 |
Other Current Assets, Total | 0.144 |
- Annual
- Quarterly
2022 | 2021 | 2020 | 2019 | |
---|---|---|---|---|
Net income/Starting Line | -11.965 | -26.477 | -66.524 | -85.422 |
Cash From Operating Activities | -71.129 | -81.19 | -55.568 | -71.787 |
Cash From Operating Activities | 8.21 | 8.241 | 8.351 | 6.749 |
Non-Cash Items | -68.403 | -62.397 | 4.974 | 4.588 |
Cash Interest Paid | 2.668 | 1.123 | 0 | 0 |
Changes in Working Capital | 1.029 | -0.557 | -2.369 | 2.298 |
Cash From Investing Activities | 4.845 | -8.22 | -0.268 | -8.125 |
Capital Expenditures | -1.048 | -0.22 | -0.318 | -8.125 |
Other Investing Cash Flow Items, Total | 5.893 | -8 | 0.05 | 0 |
Cash From Financing Activities | -1.446 | 266.983 | 2.052 | -0.074 |
Financing Cash Flow Items | 0 | -3.945 | 0 | 0 |
Issuance (Retirement) of Stock, Net | 0.535 | 0.598 | 0.301 | 1.218 |
Issuance (Retirement) of Debt, Net | -1.981 | 270.33 | 1.751 | -1.292 |
Net Change in Cash | -67.73 | 177.573 | -53.784 | -79.986 |
Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 | |
---|---|---|---|---|---|
Net income/Starting Line | -36.969 | -11.965 | -8.245 | 17.036 | -19.832 |
Cash From Operating Activities | -18.641 | -71.129 | -52.17 | -35.366 | -18.797 |
Cash From Operating Activities | 2.073 | 8.21 | 6.096 | 4.061 | 2.04 |
Non-Cash Items | 16.414 | -68.403 | -53.13 | -56.087 | -1.396 |
Cash Interest Paid | 0.881 | 2.668 | 1.867 | 1.165 | 0.563 |
Changes in Working Capital | -0.159 | 1.029 | 3.109 | -0.376 | 0.391 |
Cash From Investing Activities | -1.152 | 4.845 | -0.367 | -0.156 | -0.022 |
Capital Expenditures | -1.152 | -1.048 | -0.367 | -0.156 | -0.022 |
Cash From Financing Activities | -0.409 | -1.446 | -1.234 | -0.945 | -0.461 |
Financing Cash Flow Items | 0 | 0 | 0 | 0 | |
Issuance (Retirement) of Stock, Net | 0.119 | 0.535 | 0.229 | 0.012 | 0.001 |
Issuance (Retirement) of Debt, Net | -0.528 | -1.981 | -1.463 | -0.957 | -0.462 |
Net Change in Cash | -20.202 | -67.73 | -53.771 | -36.467 | -19.28 |
Other Investing Cash Flow Items, Total | 5.893 | 0 | 0 |
Trading calculator
Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).
- 1:1
- 20
- 100
- 500
- 1000
- 10000
Humacyte, Inc. Company profile
About Humacyte Inc
Humacyte, Inc. (Humacyte), formerly Alpha Healthcare Acquisition Corp., is a clinical-stage biotechnology platform company developing universally implantable bioengineered human tissue at commercial scale. The Company uses its technology platform to engineer and manufacture human acellular vessels (HAVs). The HAVs are designed to be implanted into any patient without inducing a foreign body response or leading to immune rejection. It is developing a portfolio (or cabinet) of HAVs with varying diameters and lengths. The HAV cabinet offers treatment solution in various clinical areas within vascular repair, reconstruction and replacement market, including trauma, AV access for hemodialysis, peripheral arterial disease (PAD), and coronary artery bypass grafting (CABG). In addition, the Company develops HAVs for pediatric heart surgery and the delivery of cellular therapies, including pancreatic islet cell transplantation to treat Type 1 diabetes.
Financial summary
BRIEF: For the nine months ended 30 September 2021, Humacyte Inc revenues increased from $0K to $1.1M. Net loss applicable to common stockholders increased from $19K to $69.1M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Basic Earnings per Share excluding Extraordinary Items totaled to -$1.91.
Industry: | Biotechnology & Medical Research (NEC) |
2525 East North Carolina Highway 54
DURHAM
NORTH CAROLINA 27713
US
Income Statement
- Annual
- Quarterly
News
A way forward: a roundup of recent central bank decisions
Five of the world’s most significant central banks delivered policy this week. We review the decisions and discuss their impact on the markets.
12:47, 22 March 2024Bank of Japan Preview: will the BOJ end negative interest rates?
The Bank of Japan meets on Tuesday 19th of March. We preview what to expect from the BOJ decision and how it might impact the USD/JPY and Nikkei 225.
08:44, 18 March 2024Higher CPI leaves traders unfazed as US equities continue to build momentum
The latest US CPI reading hasn’t gone how the Federal would have hoped. Consumer prices came in higher than expected in February for the third month in a row.
12:42, 15 March 2024Four reasons why Bitcoin is surging to record highs
Bitcoin has surged to record highs. We discuss the four factors pushing Bitcoin higher and analyse the technicals of the cryptocurrency’s technicals.
10:18, 14 March 2024China’s National People’s Congress: The markets have again been left wanting more
China’s National People’s Congress (NPC) is underway, and the markets have so far been disappointed by what’s been delivered by the country’s central government. We look at some of the significant takeaways from the event, discuss China’s current economic conditions, and analyse the China A50.
08:23, 8 March 2024Central Banks: which one will cut first?
Central banks dominate the calendar in March and markets try to anticipate which one will be the first one to cut
13:14, 6 March 2024Nvidia (NVDA) confronts high expectations for Q4 results
Nvidia is arguably the hottest company on the planet. The company reports its Q4 results after the closing bell on Wednesday, the 21st of February. We preview what to expect from Nvidia’s earnings and analyse the technicals of its stock price.
12:13, 20 February 2024People also watch
Still looking for a broker you can trust?
Join the 580.000+ traders worldwide that chose to trade with Capital.com